Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 29 January 2009, doi:10.1136/bmj.b344
Cite this as: BMJ 2009;338:b344
Fiona Godlee, editor, BMJ
fgodlee@bmj.com
| The first 150 words of the full text of this article appear below. |
NICE (the National Institute for Health and Clinical Excellence) is 10 years old. Controversial from its inception and constantly in the public eye, NICEs survival alone is surely something to celebrate. A search on bmj.com for the past 10 years finds the institute mentioned in three articles a week on average. Looking back over this coverage, my sense is that the BMJ has shown support for NICE by being a critical friend. This week we continue that tradition with a cluster of articles challenging NICE on several fronts, as well as a podcast interview with its chief executive Andrew Dillon (http://podcasts.bmj.com/bmj). NICEs chairman Michael Rawlins has been shortlisted for the BMJ Groups lifetime achievement award (doi:10.1136/bmj.b275). You can vote for the winner on bmj.com.
So what are some of the challenges facing NICE? One is its arbitrary threshold for deciding which drugs are cost effective
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses